Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 287, Issue 2, 1998, Pages 567-577

  Campbell, Duncan J ^a   Anastasopoulos, Frank ^a   Duncan, Ann Maree ^a   James, Gail M ^a   Kladis, Athena ^a   Briscoe, Todd A ^a  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; PERINDOPRIL; SINORPHAN; UNCLASSIFIED DRUG;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HEART FAILURE; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINOGEN; ANIMALS; BLOOD PRESSURE; BODY WEIGHT; BRADYKININ; CYCLIC GMP; DIURESIS; ELECTROLYTES; HEART; MALE; NEPRILYSIN; ORGAN SIZE; PEPTIDYL-DIPEPTIDASE A; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RENIN;

EID: 0032456219     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Anastasopoulos F, Leung R, Kladis A, James GM, Briscoe TA, Gorski TP and Campbell DJ (1998) Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes. J Pharmacol Exp Ther 284:799-805.
2. Boomsma F, De Bruyn JHB, Derkx FHM and Schalekamp MADH (1981) Opposite effects of captopril on angiotensin I-converting enzyme 'activity' and 'concentration'; relation between enzyme inhibition and long-term blood pressure response. Clin Sci 60:491-498.
3. Bruneval P, Hinglais N, Alhenc-Gelas F, Tricottet V, Corvol P, Menard J, Camilleri JP and Bariety J (1986) Angiotensin I converting enzyme in human intestine and kidney. Ultrastructural and immunohistochemical localization. Histochemistry 85:73-80.
4. Campbell DJ (1993) Metabolism of prorenin, renin, angiotensinogen, and the angiotensins by tissues, in The Renin-Angiotensin System (Robertson JIS and Nicholls MG eds) pp 23.1-23.23, Gower Medical Publishing, London.
5. Campbell DJ, Duncan A-M, Kladis A and Harrap SB (1995a) Converting enzyme inhibition and its withdrawal in spontaneously hypertensive rats. J Cardiovasc Pharmacol 26:426-436.
6. Campbell DJ, Kladis A and Duncan A-M (1993a) Nephrectomy, converting enzyme inhibition and angiotensin peptides. Hypertension 22:513-522.
7. Campbell DJ, Kladis A and Duncan A-M (1993b) Bradykinin peptides in kidney, blood, and other tissues of the rat. Hypertension 21:155-165.
8. Campbell DJ, Kladis A and Duncan A-M (1994) Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 23:439-449.
9. Campbell DJ, Lawrence AC, Towrie A, Kladis A and Valentijn AJ (1991) Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension 18:763-773.
10. Campbell DJ, Lawrence AC, Kladis A and Duncan A-M (1995b) Strategies for measurement of angiotensin and bradykinin peptides and their metabolites in central nervous system and other tissues, in Methods in Neurosciences, Vol. 23: Peptidases and Neuropeptide Processing (Smith AI ed) pp 328-343, Academic Press, Orlando, FL.
11. Clark AL and Coats AJS (1995) Severity of heart failure and dosage of angiotensin converting enzyme inhibitors. Br Med J 310:973-974.
12. Crozier IG, Ikram H and Nicholls MG (1993) Angiotensin-converting enzyme inhibitors in the treatment of heart failure, in The Renin-Angiotensin System (Robertson JIS and Nicholls MG eds) pp 93.1-93.21, Gower Medical Publishing, London.
13. Duncan A-M, Burrell LM, Kladis A and Campbell DJ (1996) Effects of angiotensin converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction. J Cardiovasc Pharmacol 28:746-754.
14. Dussaule J-C, Grangé J-D, Wolf J-P, Lecomte JM, Gros C, Schwartz JC, Bodin F and Ardaillou R (1991) Effect of sinorphan, an enkephalinase inhibitor, on plasma atrial natriuretic factor and sodium urinary excretion in cirrhotic patients with ascites. J Clin Endocrinol Metab 72:653-659.
15. Eisner D, Müntze A, Kromer EP and Riegger GAJ (1992) Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol 70:494-498.
16. Erdos EG (1990) Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension 16:363-370.
17. Favrat B, Burnier M, Nussberger J, Lecomte JM, Brouard R, Waeber B and Brunner HR (1995) Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J Hypertens 13:797-804.
18. Fournié-Zaluski M-C, Lucas E, Waksman G and Roques BP (1984) Differences in the structural requirements for selective interaction with neutral metalloendopeptidase (enkephalinase) or angiotensin-converting enzyme. Molecular investigation by use of new thiol inhibitors. Eur J Biochem 139:267-274.
19. 125I]RB104, a potent inhibitor of neutral endopeptidase 24.11, and its use in detecting nanogram quantities of the enzyme by "inhibitor gel electrophoresis." Proc Natl Acad Sci USA 89:6388-6392.
20. Graf K, Koehne P, Gräfe M, Zhang M, Auch-Schwelk W and Fleck E (1995) Regulation and differential expression of neutral endopeptidase 24.11 in human endothelial cells. Hypertension 26:230-235.
21. Hansson L, Dahlöf B, Himmelmann A and Svensson A (1993) Angiotensin-converting enzyme inhibitors in the treatment of essential hypertension, in The Renin-Angiotensin System (Robertson JIS and Nicholls MG eds) pp 91.1-91.24, Gower Medical Publishing, London.
22. Helin K, Tikkanen I, Hohenthal U and Fyhrquist F (1994) Inhibition of either angiotensin-converting enzyme or neutral endopeptidase induces both enzymes. Eur J Pharmacol 264:135-141.
23. Hui KY, Holtzman EJ, Quinones MA, Hollenberg NK and Haber E (1988) Design of rat renin inhibitory peptides. J Med Chem 31:1679-1686.
24. Johansen KB, Marstein S and Aas P (1987) Automated method for the determination of angiotensin-converting enzyme in serum. Scand J Clin Lab Invest 47:411-414.
25. Lecomte J-M, Baumer P, Lim C, Duchier J, Cournot A, Dussaule JC, Ardaillou R, Gros C, Chaignon B, Souque A and Schwartz J-C (1990) Stereoselective protection of exogenous and endogenous atrial natriuretic factor by enkephalinase inhibitors in mice and humans. Eur J Pharmacol 179:65-73.
26. Linz W, Wiemer G, Gohlke P, Unger T and Scholkens BA (1995) Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 47:25-49.
27. Missouris CG and MacGregor GA (1997) The use of angiotensin-converting enzyme inhibitors in the treatment of heart failure in hospital practice. Postgrad Med J 73:409-411.
28. Ondetti MA, Rubin B and Cushman DW (1977) Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents. Science 196:441-444.
29. Piedimonte G, Nadel JA, Long CS and Hoffman JIE (1994) Neutral endopeptidase in the heart: Neutral endopeptidase inhibition prevents isoproterenol-induced myocardial hypoperfusion in rats by reducing bradykinin degradation. Circ Res 75: 770-779.
30. Pouleur H (1993) High or low dose of angiotensin-converting enzyme inhibitor in patients with left ventricular dysfunction? Cardiovasc Drugs Ther 7:891-892.
31. Rademaker MT, Charles CJ, Espiner EA, Nicholls MG, Richards AM and Kosoglou T (1996) Neutral endopeptidase inhibition: Augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure. Clin Sci 91:283-291.
32. Richards AM, Wittert GA, Espiner EA, Yandle TG, Ikram H and Frampton C (1992) Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ Res 71:1501-1507.
33. Richards M, Espiner E, Frampton C, Ikram H, Yandle T, Sopwith M and Cussans N (1990) Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects. Hypertension 16:269-276.
34. Roques BP, Noble F, Daugé V, Fournié-Zaluski M-C and Beaumont A (1993) Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 45:87-146.
35. Schmitt F, Martinez F, Ikeni A, Savoiu C, Natov S, Laborde K, Lacour B, Grünfeld J-P and Hannedouche T (1994) Acute renal effects of neutral endopeptidase inhibition in humans. Am J Physiol 267:F20-F27.
36. Schriefer JA, Broudy EP and Hassen AH (1996) Endopeptidase inhibitors decrease myocardial ischemia/reperfusion injury in an in vivo rabbit model. J Pharmacol Exp Ther 278:1034-1039.
37. Seymour AA, Asaad MM, Lanoce VM, Fennell SA, Cheung HS and Rogers WL (1993) Inhibition of neutral endopeptidase 3.4.24.11 in conscious dogs with pacing induced heart failure. Cardiovasc Res 27:1015-1023.
38. Smits GJ, McGraw DE and Trapani AJ (1990) Interaction of ANP and bradykinin during endopeptidase 24.11 inhibition: Renal effects. Am J Physiol 258:F1417-F1424.
39. Stasch JP, Hirth-Dietrich C, Ganten D and Wegner M (1996) Renal and antihypertensive effects of neutral endopeptidase inhibition in transgenic rats with an extra renin gene. Am J Hypertens 9:795-802.
40. Sybertz EJ, Chiu PJS, Vemulapalli S, Watkins R and Haslanger MF (1990) Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826. An orally active neutral metalloendopeptidase inhibitor. Hypertension 15:152-161.
41. Trippodo NC, Panchal BC and Fox M (1995) Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure. J Pharmacol Exp Ther 272:619-627.
42. Ura N, Carretero OA and Erdos EG (1987) Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int 32:507-513.
43. Wegner M, Hirth-Dietrich C and Stasch JP (1996) Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure. Cardiovasc Res 31:891-898.
44. Willenbrock R, Scheuermann M, Höhnel K, Luft FC and Dietz R (1996) Acute and chronic neutral endopeptidase inhibition in rats with aortocaval shunt. Hypertension 27:1259-1266.
45. Yamamoto K, Chappell MC, Brosnihan KB and Ferrario CM (1992) In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension 19:692-696.
46. Yandle T, Richards M, Smith M, Charles C, Livesey J and Espiner E (1992) Assay of endopeptidase-24.11 activity in plasma applied to in vivo studies of endopeptidase inhibitors. Clin Chem 38:1785-1791.
47. Yang XP, Liu YH, Peterson E and Carretero OA (1997) Effect of neutral endopeptidase 24.11 inhibition on myocardial ischemia/reperfusion injury: The role of kinins. J Cardiovasc Pharmacol 29:250-256.